PapersPMID:41342306
Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).
- findings
- 2
- compound
- 1
- endpoints
- 2
- Study, every finding
- meta-analysis
No finding here moved its endpoint.
What did not
How to read these marks →“Methylphenidate may not affect serious adverse events (risk ratio (RR) 0.80, 95% CI 0.39 to 1.67; I² = 0%; 26 trials, 3673 participants; very low-certainty evidence).”
- Participants
- 3,673
- Effect
- 0.8 risk ratio, 95% CI 0.39 to 1.67
- Population
- children and adolescents with ADHD; primary outcome (serious adverse events)
“Methylphenidate may improve teacher-rated general behaviour versus placebo (SMD -0.62, 95% CI -0.91 to -0.33; I² = 68%; 7 trials 792 participants; very low-certainty evidence), but may not affect quality of life (SMD 0.40, 95% CI -0.03 to 0.83; I² = 81%; 4 trials, 608 participants; very low-certainty evidence).”
- Participants
- 608
- Effect
- 0.4 standardised mean difference, 95% CI −0.03 to 0.83
- Population
- children and adolescents with ADHD; secondary outcome (quality of life), instrument not named by the review
Study record
- Design
- meta-analysis
- Species
- human
- Population
- children and adolescents (aged 3-21, mean 9.8 years) with ADHD; 212 randomised trials (16,302 participants randomised, 165 trials with usable data on 14,271 participants)
- Participants
- 16,302
- Comparator
- not stated in the paper / placebo
- Duration
- not reported
- Endpoints measured
- 5